Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037005 | 0.85 | ROCK1 (0.50) | ROCK1ROCK2CNR2HDAC4HDAC7 | |
| SCHEMBL18162818 | 0.85 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL26673268 | 0.84 | ALDH1A1 (0.43) | ROCK1ROCK2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1273411 | 0.84 | ALDH1A1 (0.43) | ROCK1ROCK2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL23100732 | 0.83 | ROCK1 (0.53) | ROCK1ROCK2CNR2HDAC4HDAC7 | |
| SCHEMBL3585946 | 0.83 | ROCK1 (0.53) | ROCK1ROCK2CNR2HDAC4HDAC7 | |
| SCHEMBL14393867 | 0.82 | ROCK1 (0.52) | ROCK1ROCK2CNR2HDAC4HDAC7 | |
| SCHEMBL14393694 | 0.82 | ROCK1 (0.52) | ROCK1ROCK2CNR2HDAC4HDAC7 | |
| SCHEMBL18162789 | 0.82 | KCNQ3 (0.49) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL3401623 | 0.81 | ALDH1A1 (0.71) | ROCK1ROCK2ALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| CN-102056927-B | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC | 2014-06-25 | — | — | CN | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | ROCK1 358/4885ROCK2 485/4885ALDH1A1 3509/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | ROCK1 600/4885ROCK2 722/4885ALDH1A1 4129/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | ROCK1 2117/4885ROCK2 2305/4885ALDH1A1 1896/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | ROCK1 2117/4885ROCK2 2305/4885ALDH1A1 1896/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | ROCK1 2117/4885ROCK2 2305/4885ALDH1A1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.